# US 2013/0296322 A1 · Serotonin reuptake inhibitors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0296322 A1
- Document ID: US20130296322A1
- Status: Published application
- Kind: A1
- Application number: 13/936,312
- Filed: 2013-07-08
- Published: 2013-11-07
- Earliest claimed: 2010-12-03
- Assignees: Theravance, Inc.
- Inventors: Eric L. Stangeland; Lori Jean Van Orden; Daisuke Roland Saito
- Web page: https://patentgrep.com/patent/US20130296322A1

## CPC

- C07D 207/09: Radicals substituted by nitrogen atoms, not forming part of a nitro radical
- A61K 31/40: having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K 31/41: having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K 31/4155: non condensed and containing further heterocyclic rings
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/422: not condensed and containing further heterocyclic rings
- A61K 31/4245: Oxadiazoles
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/12: Antihypertensives
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/10: for osteoporosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

In one aspect, the invention relates to compounds of formula I: where Y, R1, R2, n, and Q are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.

## Claims

### Claim 1

(canceled)

### Claim 2 (depends on 20)

The method of claim 20, where Y is —CH—.

### Claim 3 (depends on 20)

The method of claim 20, where R1 is selected from —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms, and —NO2.

### Claim 4 (depends on 3)

The method of claim 3, where R1 is —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms.

### Claim 5 (depends on 4)

The method of claim 4, where R1 is —CF3.

### Claim 6 (depends on 20)

The method of claim 20, where R2 is selected from hydrogen and —CN.

### Claim 7 (depends on 20)

The method of claim 20, where R2 is hydrogen.

### Claim 8 (depends on 20)

The method of claim 20, where n is 1.

### Claim 9 (depends on 20)

The method of claim 20, where Q is —NR3SO2R4.

### Claim 10 (depends on 9)

The method of claim 9, where R3 is selected from hydrogen, —CH3, and —C(O)CH3.

### Claim 11 (depends on 9)

The method of claim 9, where R4 is selected from —CH3; —CH2CH3; —CH(CH3)2; cyclopropyl; —NH2; —NH(CH3); —N(CH3)2; —CH2SO2—CH3; pyrazole; pyrazole substituted with —CH3; triazole; morpholine; benzoxadiazole; and phenyl optionally substituted with R9; where R9 is selected from —CN, —COOH, —NO2, —OCH3, —C(O)NHCH3, —NHC(O)CH3, —SO2—CH3, —SO2—NH2, —SO2—NHCH3, oxazole, pyrimidine, tetrazole, pyrazole, and pyrazole substituted with two methyl groups.

### Claim 12 (depends on 20)

The method of claim 20, where Q is —SO2NR5R6.

### Claim 13 (depends on 12)

The method of claim 12, where R5 is selected from hydrogen and —CH3.

### Claim 14 (depends on 12)

The method of claim 12, where R6 is selected from hydrogen, —CH3, and benzyl.

### Claim at position 15

15-19. (canceled)

### Claim 20

A method of treating a disease selected from pulmonary arterial hypertension, gastrointestinal disorders, cancer, rheumatoid arthritis, osteoarthritis, osteoporosis, and diabetes, comprising administering a therapeutically effective amount of a compound of formula I:
where:
Y is —CH— or —N—;
R1 is selected from halo; —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —C0-1alkylene-phenyl; —O—C0-3alkylene-phenyl; —SO2—C1-6alkyl; —C(O)NH2; and —NO2;
R2 is selected from hydrogen, halo, and —CN;
n is an integer from 1 to 3;
Q is selected from —NR3SO2R4 and —SO2NR5R6;
R3 is selected from hydrogen, —C1-6alkyl, and —C(O)C1-6alkyl;
R4 is selected from —C1-6alkyl; —C1-6cycloalkyl; —NR7R8; —CH2SO2—C1-6alkyl; pyrazole optionally substituted with —CH3; triazole; morpholine; benzoxadiazole; and phenyl optionally substituted with R9; where R7 and R8 are independently selected from hydrogen and —C1-6alkyl; and R9 is selected from —CN, —COOH, —NO2, —C0-2alkylene-O—C1-6alkyl, —C(O)NR7R8, —NR7C(O)—C1-6alkyl, —SO2—C1-6alkyl, —SO2—NR7R8, and a nitrogen-containing heteroaryl optionally substituted with 1 or 2-CH3 groups;
R5 is selected from hydrogen and —C1-6alkyl; and
R6 is selected from hydrogen, —C1-6alkyl, and benzyl;
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20, where the disease is pulmonary arterial hypertension.

### Claim 22

A method of treating a patient that is in need of anti-platelet therapy, comprising administering a therapeutically effective amount of a compound of formula I:
where:
Y is —CH— or —N—;
R1 is selected from halo; —C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —O—C1-6alkyl optionally substituted with 1 to 5 fluoro atoms; —C0-1alkylene-phenyl; —O—C0-3alkylene-phenyl; —SO2—C1-6 alkyl; —C(O)NH2; and —NO2;
R2 is selected from hydrogen, halo, and —CN;
n is an integer from 1 to 3;
Q is selected from —NR3SO2R4 and —SO2NR5R6;
R3 is selected from hydrogen, —C1-6alkyl, and —C(O)C1-6alkyl;
R4 is selected from —C1-6alkyl; —C1-6cycloalkyl; —NR7R8; —CH2SO2—C1-6alkyl; pyrazole optionally substituted with —CH3; triazole; morpholine; benzoxadiazole; and phenyl optionally substituted with R9; where R7 and R8 are independently selected from hydrogen and —C1-6alkyl; and R9 is selected from —CN, —COOH, —NO2, —C0-2alkylene-O—C1-6alkyl, —C(O)NR7R8, —NR7C(O)—C1-6 alkyl, —SO2—C1-6 alkyl, —SO2—NR7R8, and a nitrogen-containing heteroaryl optionally substituted with 1 or 2-CH3 groups;
R5 is selected from hydrogen and —C1-6alkyl; and
R6 is selected from hydrogen, —C1-6alkyl, and benzyl;
or a pharmaceutically acceptable salt thereof.
